Brachytherapy's use in prostate Ca is on the rise

Winston-Salem, NC--Well over one-third of men with localized prostatecancer are opting for brachytherapy as their primary treatment, accordingto a recently published study. Past and current data indicate the proportionof prostate cancer patients choosing brachytherapy has grown from 1.4% in1992 to 3.0% in 1995 to 36% in 1999-the latest year for which comprehensivedata are available.

Related Videos

Related Content

Advertisement

November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke

“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

November 19th 2024

Dean Laganosky, M.D., named Urology Trailblazer for 2024

MidLantic Urology

This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.

November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke

At the time of data cutoff, 71% of patients achieved a complete response following treatment.

Related Content

Advertisement

November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke

“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

November 19th 2024

Dean Laganosky, M.D., named Urology Trailblazer for 2024

MidLantic Urology

This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.

November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke

At the time of data cutoff, 71% of patients achieved a complete response following treatment.